Tyra Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M |
| Operating expenses | $132.8M | $104.2M | $79.9M | $58.9M | $26.3M |
| Operating income | -$132.8M | -$104.2M | -$79.9M | -$58.9M | -$26.3M |
| Income tax expense | $0 | $0 | $0 | $2,000 | $1,000 |
| Net income | -$119.9M | -$86.5M | -$69.1M | -$55.3M | -$26.3M |
| Balance Sheet | |||||
| Cash and equivalents | $77.4M | $92.0M | $58.0M | $251.2M | $302.2M |
| Current assets | $265.4M | $347.5M | $211.7M | $257.3M | $304.1M |
| Total assets | $282.6M | $363.6M | $225.9M | $266.2M | $306.7M |
| Current liabilities | $18.1M | $14.6M | $15.3M | $5.7M | $3.6M |
| Total liabilities | $23.4M | $20.4M | $21.6M | $8.4M | $5.0M |
| Stockholders' equity | $259.2M | $343.2M | $204.3M | $257.8M | $301.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$95.1M | -$69.8M | -$50.1M | -$50.3M | -$23.7M |
| Depreciation and amortization | $546,000 | $519,000 | $357,000 | $296,000 | $140,000 |
| Stock-based compensation | $28.0M | $22.8M | $13.5M | $10.6M | $2.9M |
| Capital expenditure | $141,000 | $664,000 | $770,000 | $559,000 | $661,000 |
| Free cash flow | -$95.3M | -$70.4M | -$50.9M | -$50.8M | -$24.4M |
Shares outstanding 59.5M · Free float 40.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.